ImmunityBio's allogeneic CD19 cell therapy shows complete response beyond 15 months [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
months of complete response in patients with Waldenström Non-Hodgkins lymphoma, a rare B-cell malignancy. In the ongoing Phase I QUILT-106 study (NCT06334991), CAR-NK, in combination with rituximab, led to sustained complete responses with durations extending over 15 months, with 100% disease control observed to date. The trial enrolled patients who failed to respond to standard of care (SoC). Patients received eight doses of cell therapy in the outpatient setting without lymphodepletion, which requires chemotherapy. Patients received a total of eight doses of CAR-NK and six doses of rituximab. Four patients with Waldenström Non-Hodgkin lymphoma were enrolled in the study, and all remain in clinical disease control. Two of these patients are continuing to demonstrate durable complete remission at seven and 15 months, respectively. Both responses are ongoing, despite the patients receiving no additional treatment. The patient with 15-month complete remission presented with appr
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewswire
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent LymphomasBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/26/26 - Form 8-K
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- IBRX's page on the SEC website